Rejuvenate Bio
Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans
Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans
Rejuvenate Bio is a biotechnology startup founded in 2017, aiming to combat chronic age-related diseases. The company's focus is on leveraging gene expression and epigenetic reprogramming to reverse pre-existing conditions such as heart disease, metabolic disease, and kidney failure in humans. With its slogan "Targeting the core drivers of chronic age-related diseases to reverse pre-existing conditions in humans," Rejuvenate Bio has garnered attention in the health care industry. In April 27, 2021, the company secured a significant $14.58M in a Venture Round investment. Despite the absence of specific headquarters information, the recent investment highlights investor confidence in the potential of Rejuvenate Bio's innovative approach. This substantial funding could signify a pivotal point for the company's trajectory, as it continues to make strides in transforming the landscape of age-related disease treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $4.00M | 1 | California Institute for Regenerative Medicine | 01 Jul 2024 |
| Series A | $14.58M | 5 |
|
12 Apr 2021 |
| Seed Round | Unknown | 3 |
|
01 Jun 2018 |
No recent news or press coverage available for Rejuvenate Bio.
We care about your data, and we'd love to use cookies make your experience better.
